These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 20168352

  • 1. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
    Wysocki PJ, Kazimierczak U, Suchorska W, Kotlarski M, Malicki J, Mackiewicz A.
    Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
    [Abstract] [Full Text] [Related]

  • 2. Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.
    Suchorska WM, Dams-Kozlowska H, Kazimierczak U, Wysocki PJ, Mackiewicz A.
    Expert Opin Biol Ther; 2011 Dec; 11(12):1555-67. PubMed ID: 21995459
    [Abstract] [Full Text] [Related]

  • 3. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
    Kinoshita Y, Kono T, Yasumoto R, Kishimoto T, Wang CY, Haas GP, Nishisaka N.
    J Immunother; 2001 Dec; 24(3):205-11. PubMed ID: 11394497
    [Abstract] [Full Text] [Related]

  • 4. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
    Doehn C, Esser N, Pauels HG, Kiessig ST, Stelljes M, Grossmann A, Jocham D, Drevs J.
    Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267
    [Abstract] [Full Text] [Related]

  • 5. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M, Hara I, Furukawa J, Oniki S, Nagai H, Miyake H, Fujisawa M.
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [Abstract] [Full Text] [Related]

  • 6. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
    Fukuhara H, Matsumoto A, Kitamura T, Takeuchi T.
    BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration.
    Hara I, Nagai H, Miyake H, Yamanaka K, Hara S, Micallef MJ, Kurimoto M, Gohji K, Arakawa S, Ichihashi M, Kamidono S.
    Cancer Gene Ther; 2000 Jan; 7(1):83-90. PubMed ID: 10678360
    [Abstract] [Full Text] [Related]

  • 8. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Estrogen receptor-binding fragment-associated antigen 9 is a tumor-promoting and prognostic factor for renal cell carcinoma.
    Ogushi T, Takahashi S, Takeuchi T, Urano T, Horie-Inoue K, Kumagai J, Kitamura T, Ouchi Y, Muramatsu M, Inoue S.
    Cancer Res; 2005 May 01; 65(9):3700-6. PubMed ID: 15867365
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A.
    Cancer Res; 2001 Nov 01; 61(21):7925-33. PubMed ID: 11691814
    [Abstract] [Full Text] [Related]

  • 14. Gene therapy for murine renal cell carcinoma using genetically engineered tumor cells to secrete interleukin-12.
    Kasaoka Y, Nakamoto T, Wang J, Usui T, Hamada H.
    Hiroshima J Med Sci; 2000 Mar 01; 49(1):29-35. PubMed ID: 10824454
    [Abstract] [Full Text] [Related]

  • 15. Trafficking of 'immune' CD4(+)/CD8(+)T-lymphocytes into the RENCA tumour microcirculation in vivo in mice.
    Ali SA, Rees RC, Anderson DQ, Reed MW, Goepel JR, Brown NJ.
    Br J Cancer; 2000 Oct 01; 83(8):1061-8. PubMed ID: 10993655
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H, Zhou FJ, Wang QJ, Qin ZK, Huang LX, Liu ZW, Han H, Li YQ, Chen SP, Xia JC.
    Ai Zheng; 2006 May 01; 25(5):625-30. PubMed ID: 16687087
    [Abstract] [Full Text] [Related]

  • 17. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
    Chagnon F, Tanguay S, Ozdal OL, Guan M, Ozen ZZ, Ripeau JS, Chevrette M, Elhilali MM, Thompson-Snipes LA.
    Clin Cancer Res; 2005 Feb 01; 11(3):1302-11. PubMed ID: 15709202
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.